M3VAS Validation in Polish Population - Trial NCT06412562
Access comprehensive clinical trial information for NCT06412562 through Pure Global AI's free database. This phase not specified trial is sponsored by Medical University of Gdansk and is currently Recruiting. The study focuses on Depressive Disorder. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Medical University of Gdansk
Timeline & Enrollment
N/A
May 09, 2024
Sep 01, 2026
Primary Outcome
The Maudsley 3-item Visual Analogue Scale (M3VAS)
Summary
Low mood and anhedonia represent the fundamental symptoms of major depressive disorder (MDD).
 Nevertheless, there is currently no standardized visual analogue scale available to assess
 the extent of both symptoms concurrently. The Maudsley 3-item Visual Analogue Scale (M3VAS)
 is a newly developed tool for participants to self-assess core symptoms of depression: mood
 quality, pleasure experience (anhedonia), and suicidality. Despite suicidality not being a
 primary symptom, it is included due to its critical relevance to safety. Participants will be
 instructed to rate the intensity and frequency of their experiences over the preceding two
 weeks by marking a 100 mm ungraded line. A researcher will then assign a numerical value
 based on the mark's position, utilizing the left edge as 0 and the right as 100. The total
 score range, combining the three symptoms, ranged from 0 (minimum) to 300 (maximum). The
 M3VAS exhibited good psychometric properties in British population. In this study, the
 objective is to assess the psychometric properties of the scale within the Polish population
 diagnosed with major depressive episode within major depressive disorder or bipolar disorder.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06412562
Non-Device Trial

